Christian Waage
Christian Waage's purchase track record
Christian Waage has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/20/2023 | GOSS | $22K | +8.7% | -22.1% | +12.7% |
| 7/15/2022 | GOSS | $50K | +9.8% | -78.9% | +3.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
GOSS Submits NDA for Seralutinib in Pulmonary Arterial Hypertension. Gossamer Bio has filed a new drug application with the U.S. FDA for Seralutinib, a treatment aimed at pulmonary arterial hypertension. The filing follows a broader after‑market move in health‑care stocks, with GOSS among the 12 that saw activity Friday. The submission could influence the company’s future regulatory path and investor interest.
Transaction History
| HRTX | ▲ Buy | Grant | 53,960 | $0 | 1/30/2026 | View on chart |
| GOSS | ▲ Buy | Grant | 84,500 | $0 | 1/2/2026 | View on chart |
| GOSS | ▲ Buy | Grant | 125,000 | $0 | 10/1/2025 | View on chart |
| HRTX | ▲ Buy | Grant | 17,950 | $0 | 1/30/2025 | View on chart |
| GOSS | ▼ Sell | Open Market | 6,430 | $7K | 3/27/2024 | View on chart |
| HRTX | ▲ Buy | Grant | 13,948 | $0 | 1/19/2024 | View on chart |
| GOSS | ▲ Buy | Grant | 13,504 | $25K | 7/24/2023 | View on chart |
| GOSS | ▲ Buy | Open Market | 18,500 | $22K | 3/20/2023 | View on chart |
| HRTX | ▲ Buy | Grant | 38,580 | $0 | 12/16/2022 | View on chart |
| GOSS | ▲ Buy | Open Market | 6,934 | $50K | 7/15/2022 | View on chart |
| GOSS | ▼ Sell | Open Market | 10,722 | $96K | 3/23/2022 | View on chart |
| HRTX | ▲ Buy | Grant | 10,452 | $0 | 12/22/2021 | View on chart |
| HRTX | ▼ Sell | Open Market | 300 | $3K | 12/21/2021 | View on chart |
| HRTX | ▼ Sell | Open Market | 300 | $4K | 9/21/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Heron Therapeutics Signs U.S. License Deal
Heron Therapeutics has entered a multi-product development and license agreement granting it exclusive rights to market products in the U.S. The company is obligated to pay milestone and royalty payments under this new arrangement. This development provides a potential pathway for future revenue, though the stock currently trades well below the average analyst target price.
Heron Therapeutics Signs U.S. License Deal. Heron Therapeutics has entered a multi-product development and license agreement granting it exclusive rights to market products in the U.S. The company is obligated to pay milestone and royalty payments under this new arrangement. This development provides a potential pathway for future revenue, though the stock currently trades well below the average analyst target price.